Literature DB >> 9406270

Care of long-term mentally ill patients by British general practitioners.

T Burns1, T Kendrick.   

Abstract

In the United Kingdom, patients gain access to psychiatric care through general practitioners (GPs). The first of three studies conducted to assess the role of GPs in managing patients with long-term mental illness found that such patients were unevenly distributed in general practices and that GPs preferred to care for them in collaboration with psychiatric specialists. A more detailed study of 16 general practices yielded information on characteristics and care of long-term mentally ill patients, including a high rate of GP consultations for them. A third, controlled study examined the impact of teaching GPs to provide a structured assessment of long-term mentally ill patients every six months; after the intervention, only a small number of patients actually received such assessments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406270     DOI: 10.1176/ps.48.12.1586

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  3 in total

1.  Caring for seriously mentally ill patients. Qualitative study of family physicians' experiences.

Authors:  Judith Belle Brown; Barbara Lent; April Stirling; Jatinder Takhar; Joan Bishop
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

2.  Variables associated with general practitioners taking on serious mental disorder patients.

Authors:  Marie-Josée Fleury; Jean-Marie Bamvita; Jacques Tremblay
Journal:  BMC Fam Pract       Date:  2009-06-10       Impact factor: 2.497

3.  The ThRombolysis in UnconTrolled Hypertension (TRUTH) protocol: an observational study on treatment strategy of elevated blood pressure in stroke patients eligible for IVT.

Authors:  T P Zonneveld; A Algra; D W J Dippel; L J Kappelle; R J van Oostenbrugge; Y B W E M Roos; M J Wermer; H B van der Worp; P J Nederkoorn; N D Kruyt
Journal:  BMC Neurol       Date:  2015-11-23       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.